Free Trial
NASDAQ:CVKD

Cadrenal Therapeutics Q1 2025 Earnings Report

Cadrenal Therapeutics logo
$16.42 -0.36 (-2.15%)
As of 04:00 PM Eastern

Cadrenal Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.64
Beat/Miss
N/A
One Year Ago EPS
N/A

Cadrenal Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cadrenal Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
6:00PM ET

Conference Call Resources

Cadrenal Therapeutics Earnings Headlines

The next market Nvidia is positioned to dominate …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
CVKD: Preparing for Phase 3 Trial of Tecarfarin…
See More Cadrenal Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email.

About Cadrenal Therapeutics

Cadrenal Therapeutics (NASDAQ:CVKD) operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

View Cadrenal Therapeutics Profile

More Earnings Resources from MarketBeat